BridgeMD
New treatment option for Biliary Atresia
Official title Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
ClinicalTrials.gov ID: NCT07513038
What this study is testing
What is Indocyanine Green (ICG)?
Indocyanine Green (ICG) is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for biliary atresia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Biliary atresia is a rare, progressive liver disease that only affects infants. It leads to complete obstruction and scarring of the bile duct.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 to 3
You may be able to join if
- age \<3 months viable infants
- cholestasis (defined as direct bilirubin \>1)
- undergoing diagnostic HIDA scan to evaluate for biliary atresia
You likely can't join if
- kidney disease (eGFR \<60 mL/min/1.73m2)
- grossly bloody stools
- history of bowel surgery or disease
- history of allergic reaction to ICG, iodine, or shellfish
- unable to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0 days to 3 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.